[ad_1]
The European Medicines Agency (EMA), the European Union’s pharmacovigilance authority, is expected to issue a marketing authorization for the new type of coronavirus developed by Pfizer in the US and BioNTech in Germany on December 23. According to the Frankfurter Allgemeine Zeitung (FAZ).
A press conference was held in Berlin at the same time as the reports on German government and EU funds in Brussels. Jens spahn Germany’s federal health minister, who indirectly confirmed the information, said it was “very good news” for the entire EU that the EMA investigation could be completed before December 23.
He stressed that, applying the same EU rule as the UK, Germany or any other wealthier Western European member state, national competence might have been required to authorize, purchase and use the vaccine, but within twenty weeks cohesion, solidarity. He said vaccines will start in Germany no more than three to four days after the EMA permit is issued.
[ad_2]
